IRIS Accounts Production v26.1.0.640 01437361 Board of Directors 1.1.25 31.12.25 31.12.25 true false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh014373612024-12-31014373612025-12-31014373612025-01-012025-12-31014373612023-12-31014373612024-01-012024-12-31014373612024-12-3101437361ns15:EnglandWales2025-01-012025-12-3101437361ns14:PoundSterling2025-01-012025-12-3101437361ns10:Director12025-01-012025-12-3101437361ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3101437361ns10:SmallEntities2025-01-012025-12-3101437361ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-3101437361ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3101437361ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3101437361ns10:FullAccounts2025-01-012025-12-3101437361ns10:Director22025-01-012025-12-3101437361ns10:Director32025-01-012025-12-3101437361ns10:CompanySecretary12025-01-012025-12-3101437361ns10:RegisteredOffice2025-01-012025-12-3101437361ns5:CurrentFinancialInstruments2025-12-3101437361ns5:CurrentFinancialInstruments2024-12-3101437361ns5:Non-currentFinancialInstruments2025-12-3101437361ns5:Non-currentFinancialInstruments2024-12-3101437361ns5:ShareCapital2025-12-3101437361ns5:ShareCapital2024-12-3101437361ns5:SharePremium2025-12-3101437361ns5:SharePremium2024-12-3101437361ns5:CapitalRedemptionReserve2025-12-3101437361ns5:CapitalRedemptionReserve2024-12-3101437361ns5:RetainedEarningsAccumulatedLosses2025-12-3101437361ns5:RetainedEarningsAccumulatedLosses2024-12-3101437361ns5:PlantMachinery2025-01-012025-12-3101437361ns5:PlantMachinery2024-12-3101437361ns5:PlantMachinery2025-12-3101437361ns5:PlantMachinery2024-12-3101437361ns5:CostValuation2024-12-3101437361ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3101437361ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3101437361ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2025-12-3101437361ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-12-3101437361ns5:HirePurchaseContractsns5:BetweenOneFiveYears2025-12-3101437361ns5:HirePurchaseContractsns5:BetweenOneFiveYears2024-12-3101437361ns5:HirePurchaseContracts2025-12-3101437361ns5:HirePurchaseContracts2024-12-3101437361ns5:WithinOneYear2025-12-3101437361ns5:WithinOneYear2024-12-3101437361ns5:BetweenOneFiveYears2025-12-3101437361ns5:BetweenOneFiveYears2024-12-3101437361ns5:MoreThanFiveYears2025-12-3101437361ns5:MoreThanFiveYears2024-12-3101437361ns5:AllPeriods2025-12-3101437361ns5:AllPeriods2024-12-3101437361ns5:Secured2025-12-3101437361ns5:Secured2024-12-31
REGISTERED NUMBER: 01437361 (England and Wales)

























Unaudited Financial Statements for the Year Ended 31 December 2025

for

SCIMED LTD

SCIMED LTD (Registered number: 01437361)






Contents of the Financial Statements
for the Year Ended 31 December 2025




Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 7


SCIMED LTD

Company Information
for the Year Ended 31 December 2025







DIRECTORS: J Booth
Dr A J Rucklidge
P D Vanden Branden





SECRETARY: Dr A J Rucklidge





REGISTERED OFFICE: Unit 4 The Embankment Business Park
Vale Road
Stockport
Cheshire
SK4 3GN





REGISTERED NUMBER: 01437361 (England and Wales)





ACCOUNTANTS: IN Accountancy Limited
2 Station View
Bramhall Moor Lane
Hazel Grove
Stockport
Cheshire
SK7 5ER

SCIMED LTD (Registered number: 01437361)

Balance Sheet
31 December 2025

31.12.25 31.12.24
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 21,431 30,957
Investments 5 530,794 530,794
552,225 561,751

CURRENT ASSETS
Stocks 1,766,726 1,659,441
Debtors 6 2,095,982 2,666,309
Cash at bank 18,359 201,419
3,881,067 4,527,169
CREDITORS
Amounts falling due within one year 7 2,766,987 3,324,266
NET CURRENT ASSETS 1,114,080 1,202,903
TOTAL ASSETS LESS CURRENT LIABILITIES 1,666,305 1,764,654

CREDITORS
Amounts falling due after more than one year 8 (196,714 ) (312,908 )

PROVISIONS FOR LIABILITIES (5,358 ) (7,739 )
NET ASSETS 1,464,233 1,444,007

CAPITAL AND RESERVES
Called up share capital 4,078 4,078
Share premium 20,122 20,122
Capital redemption reserve 12,803 12,803
Retained earnings 1,427,230 1,407,004
SHAREHOLDERS' FUNDS 1,464,233 1,444,007

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

SCIMED LTD (Registered number: 01437361)

Balance Sheet - continued
31 December 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 May 2026 and were signed on its behalf by:





Dr A J Rucklidge - Director


SCIMED LTD (Registered number: 01437361)

Notes to the Financial Statements
for the Year Ended 31 December 2025

1. STATUTORY INFORMATION

SCIMED LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost, 25% on reducing balance and 15% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

SCIMED LTD (Registered number: 01437361)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 41 (2024 - 39 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2025
and 31 December 2025 107,152
DEPRECIATION
At 1 January 2025 76,195
Charge for year 9,526
At 31 December 2025 85,721
NET BOOK VALUE
At 31 December 2025 21,431
At 31 December 2024 30,957

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2025
and 31 December 2025 530,794
NET BOOK VALUE
At 31 December 2025 530,794
At 31 December 2024 530,794

During the previous year the company purchased 110 ordinary shares in Dublin Analytical Instruments Limited. This equates to 55% of the issued share capital of that company.

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£    £   
Trade debtors 2,005,420 2,543,752
Other debtors 90,562 122,557
2,095,982 2,666,309

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£    £   
Bank loans and overdrafts 106,647 10,360
Hire purchase contracts (see note 9) 110,057 249,571
Trade creditors 740,931 1,087,001
Taxation and social security 625,351 701,948
Other creditors 1,184,001 1,275,386
2,766,987 3,324,266

SCIMED LTD (Registered number: 01437361)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
31.12.25 31.12.24
£    £   
Bank loans - 6,137
Hire purchase contracts (see note 9) 91,714 201,771
Other creditors 105,000 105,000
196,714 312,908

9. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase
contracts
31.12.25 31.12.24
£    £   
Net obligations repayable:
Within one year 110,057 249,571
Between one and five years 91,714 201,771
201,771 451,342

Non-cancellable
operating leases
31.12.25 31.12.24
£    £   
Within one year 169,717 167,393
Between one and five years 351,326 349,219
In more than five years 191,479 241,979
712,522 758,591

10. SECURED DEBTS

The following secured debts are included within creditors:

31.12.25 31.12.24
£    £   
Bank overdraft 100,496 -
Hire purchase contracts 201,771 451,342
302,267 451,342

The Hire Purchase is secured on stocks held.

The secured bank debt relates to an Invoice Financing arrangement which is secured on the book debt of the company.

SCIMED LTD (Registered number: 01437361)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

11. RELATED PARTY DISCLOSURES

P & A SIPP

The company rents premises, under an operating lease, from P A Group SIPP, the pension scheme of the directors.
During the year rent was paid to the pension scheme totalling £51,072 (2024: £9,939).

Dublin Analytical Instruments Limited
During the previous year the company acquired a 55% holding in Dublin Analytical Instruments Limited, a company registered in Eire.

The company received management charges and reimbursement of other expenses from Dublin Analytical Instruments Limited of £22,801 (2024: £5,539) in the year.
The company also received a dividend of £39,617 (2024: £NIL) from the subsidiary.

In addition to the above the company traded with Dublin Analytical Instruments Limited as follows::

Sales - £217,382, trade debtor balance at the end of the year £85,094

Purchases - £6,191, trade creditor balance at the end of the year Debit £149

12. ULTIMATE CONTROLLING PARTY

The company is considered to be under the control of the directors acting in concert.